Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 630 participants.
Also called NCT07144956
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 630 participants
- Sponsor
- Registry
-
NCT07144956 -
2024-516468-27-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07144956. Randomized; triple masking; primary purpose treatment. Start 2025-12-15 (anticipated); primary completion 2029-12-14 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage
- Acronym
- CASH
- Condition
- Aneurysmal Subarachnoid Hemorrhage
- Intervention (Biological)
- Cilostazol (Pletal®) 100 mg Tablets
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Nimodipine group
- Lead sponsor
- Centre Hospitalier St Anne
Record details
- Record id
cardio:ct-nct07144956- Content hash
acee1a100e13be774aa08f4053a2b639240037ca2713238fe0249f93d254ec0b